Ionis lowers TRYNGOLZA outlook to ~$50M as DAWNZERA and partners carry Q3
Ionis reaffirmed total revenue, operating loss and cash guidance, but cut 2026 TRYNGOLZA sales to about $50 million from $100-110 million as its first large-indication launch ramps more slowly.
The quarter in numbers
Ionis reported third-quarter 2026 total revenue of $243 million, against $157 million a year earlier. For the nine months, revenue was $757 million versus $740 million. The nine-month comparison includes the $280 million sapablursen upfront from Ono Pharmaceutical in the second quarter of 2025. Excluding that payment, the company said revenue rose 55% in the quarter and 64% over nine months.
Operating expenses were $373 million (GAAP) versus $317 million, and $330 million non-GAAP versus $286 million. Loss from operations narrowed to $(130) million from $(160) million, and the non-GAAP loss to $(87) million from $(129) million. Over nine months the picture is less favorable: the GAAP loss widened to $(350) million from $(167) million, and the non-GAAP loss to $(218) million from $(76) million, largely because of the 2025 upfront.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Ionis Pharmaceuticals Inc: quarterly results release (SEC filing) SEC EDGAR · 09 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook
Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.
Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn
Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.
Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path
Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.